SCHEMBL1726985

SCHEMBL1726985

N#Cc1cnc(N)c(Cl)c1

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.60
MET P08581 1/20 0.44
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
LMNA P02545 1/20 0.42
GAA P10253 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
CSNK1A1 P48729 1/20 0.41
CLK4 Q9HAZ1 1/20 0.41
EGLN2 Q96KS0 4/20 0.40
MAP4K4 O95819 4/20 0.39
GRM5 P41594 2/20 0.38
CYP11B2 P19099 1/20 0.38
TRPV4 Q9HBA0 1/20 0.35
KHK P50053 1/20 0.35
HPGDS O60760 1/20 0.34
XDH P47989 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31432358 1.00 HTT (0.60) HTTMETKDM4EALDH1A1LMNA
SCHEMBL24626311 0.79 HTT (0.37) HTTMET
SCHEMBL15688896 0.79 HTT (0.60) HTTMETKDM4EALDH1A1LMNA
SCHEMBL30692233 0.79 HTT (0.60) HTTMETKDM4EALDH1A1LMNA
SCHEMBL231937 0.78 TDP1 (0.44) HTTKDM4EALDH1A1LMNAGAA
SCHEMBL31221920 0.78 TDP1 (0.44) HTTKDM4EALDH1A1LMNAGAA
SCHEMBL5765965 0.78 HTT (0.64) HTTMETKDM4EALDH1A1LMNA
SCHEMBL245286 0.77 HTT (0.62) HTTMETKDM4EALDH1A1LMNA
SCHEMBL12682515 0.75 HTT (0.60) HTTMETKDM4EALDH1A1LMNA
SCHEMBL22207146 0.75 HTT (0.50) HTTMETKDM4EALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0596491-B1 Method for halogenating an aromatic compound ISHIHARA SANGYO KAISHA (JP) 1996-07-10 EP claimed
US-5491239-A Method for halogenating an aromatic compound ISHIHARA SANGYO KAISHA LTD. (JP) 1996-02-13 US claimed
EP-0596491-A1 Method for halogenating an aromatic compound ISHIHARA SANGYO KAISHA, LTD. (JP) 1994-05-11 EP claimed
WO-2025151602-A1 HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 BRISTOL-MYERS SQUIBB COMPANY (US) 2025-07-17 WO disclosed
EP-4558495-A1 HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 Bristol-Myers Squibb Company (US) 2025-05-28 EP disclosed
US-20240109881-A1 Heteroaryl Compounds as Ligand Directed Degraders of IRAK4 BRISTOL-MYERS SQUIBB COMPANY (US) 2024-04-04 US disclosed
WO-2024020084-A1 HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 BRISTOL-MYERS SQUIBB COMPANY (US) 2024-01-25 WO disclosed
WO-2024020084-A1 HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 BRISTOL-MYERS SQUIBB COMPANY (US) 2024-01-25 WO disclosed
CN-117050007-A Compound based on urea structure, preparation method thereof and application thereof in molluscicide 云南大学 2023-11-14 CN disclosed
US-10544133-B2 Heteroaryl substituted pyridyl compounds useful as kinase modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2020-01-28 US disclosed
US-20180370956-A1 HETEROARYL SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS BRISTOL MYERS SQUIBB CO (US) 2018-12-27 US disclosed
WO-2007113276-A1 NOVEL BI-ARYL AMINES NOVARTIS AG (CH) 2007-10-11 WO disclosed
US-20070099927-A1 Aminoalkyl-pyrazinones and-pyridones as thrombin inhibitors SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) 2007-05-03 US disclosed
US-20070099927-A1 Aminoalkyl-pyrazinones and-pyridones as thrombin inhibitors SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) 2007-05-03 US disclosed
US-20070099927-A1 Aminoalkyl-pyrazinones and-pyridones as thrombin inhibitors SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) 2007-05-03 US disclosed
WO-2005040137-A1 AMINOALKYL-PYRAZINONES AND -PYRIDONES AS THROMBIN INHIBITORS SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) 2005-05-06 WO disclosed
WO-2005040137-A1 AMINOALKYL-PYRAZINONES AND -PYRIDONES AS THROMBIN INHIBITORS SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) 2005-05-06 WO disclosed
EP-0596491-B1 Method for halogenating an aromatic compound ISHIHARA SANGYO KAISHA (JP) 1996-07-10 EP disclosed
US-5491239-A Method for halogenating an aromatic compound ISHIHARA SANGYO KAISHA LTD. (JP) 1996-02-13 US disclosed
EP-0596491-A1 Method for halogenating an aromatic compound ISHIHARA SANGYO KAISHA, LTD. (JP) 1994-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10544133-B2 Heteroaryl substituted pyridyl compounds useful as kinase modulators IRAK4, IRAK3, IRAK2 HTT 4303/4885MET 1103/4885KDM4E 124/4885
US-20070099927-A1 Aminoalkyl-pyrazinones and-pyridones as thrombin inhibitors F2, F12, SERPINC1 HTT 4348/4885MET 3530/4885KDM4E 1302/4885
US-20180370956-A1 HETEROARYL SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS IRAK4, IRAK3, IRAK2 HTT 4303/4885MET 1103/4885KDM4E 124/4885
US-20240109881-A1 Heteroaryl Compounds as Ligand Directed Degraders of IRAK4 IRAK4, IRAK2, IRAK3 HTT 1426/4885MET 1262/4885KDM4E 58/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.